Corcept Therapeutics Inc CORT

NAS: CORT | ISIN: US2183521028   10/04/2026
41,91 USD (-0,80%)
(-0,80%)   10/04/2026

11 april 2026 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

7 april 2026 · Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman · Persbericht

4 april 2026 · Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman · Persbericht

1 april 2026 · Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman · Persbericht

1 april 2026 · Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky · Persbericht

31 maart 2026 · Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

28 maart 2026 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

25 maart 2026 · Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Corcept Therapeutics Incorporated(CORT) Shareholders · Persbericht

24 maart 2026 · Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately · Persbericht

18 maart 2026 · Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated · Persbericht

18 maart 2026 · CORT Shareholder Notice: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss · Persbericht

18 maart 2026 · Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - CORT · Persbericht

17 maart 2026 · Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

14 maart 2026 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

12 maart 2026 · Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

10 maart 2026 · Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

5 maart 2026 · Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

4 maart 2026 · Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky · Persbericht

3 maart 2026 · Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline · Persbericht

28 februari 2026 · Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

Mijn selecties